Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in Geneva. The company plans to showcase five presentations that will highlight its current and future strategies for migraine prevention. This includes new analyses for eptinezumab and primary phase 2b PROCEED data for the investigational treatment bocunebart. Lundbeck’s commitment to advancing migraine treatment options underscores the growing emphasis on innovative therapies in neurology.
As the prevalence of migraine disorders continues to challenge healthcare systems globally, Lundbeck’s data presentations may provide critical insights into the efficacy and safety of these emerging treatments. The findings could influence clinical practice guidelines and regulatory considerations, potentially reshaping the landscape of migraine management. Stakeholders in the pharmaceutical sector, particularly those involved in regulatory affairs, quality assurance, and clinical development, will be keenly observing these developments for implications on future market strategies.
Start your 7-day trial and see what the database can do →
